SMR 2024 | Advances in oncolytic immunotherapy for melanoma: vusolimogene oderparepvec
Gino In, MD, University of Southern California, Los Angeles, CA, comments on the potential of oncolytic immunotherapies for the treatment of advanced melanoma. The Phase III OPTiM study (NCT00769704) showed that talimogene laherparepvec (T-VEC), an FDA-approved oncolytic virus, produced the most clinical benefit to those with limited cases of advanced melanoma. Vusolimogene oderparepvec (RP1), a novel oncolytic virus genetically modified to express GM-CSF (granulocyte macrophage colony stimulating factor) and GALV (a fusogenic glycoprotein) through intratumoral injections to tumors, was assessed in the IGNYTE-3 trial (NCT06264180). RP1 demonstrated improved clinical efficacy, paving the way for new oncolytic viruses. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
